ArticleHereditary cancer in clinical practice2026
The psychosocial impact of receiving a polygenic risk score informing risk of prostate cancer.
Article in Hereditary cancer in clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03857477 (The BARCODE 1 Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The BARCODE 1 Study: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundUse of polygenic risk scores (PRS) as a risk-stratification tool in cancer screening is an area of increasing interest. The BARCODE1 study is an observational prostate cancer screening study, investigating the use of PRS to risk-stratify people by risk of prostate cancer, with those identified as higher risk invited for prostate cancer screening. Participants of BARCODE1 were invited to take part in a psychosocial sub-study aiming to explore the effect of receiving a polygenic risk score on psychological health, family risk communication and impact on health behaviours.
methods1300 participants of the BARCODE1 study were invited to complete questionnaires before and after receiving the results of their PRS. A sub-group were invited to participate in one-to-one in-depth semi-structured interviews, conducted in-person, by telephone or video-call. Interviews were audio recorded and transcribed verbatim. Data were analysed using Reflexive Thematic Analysis and the results are reported here.
resultsEighteen participants were interviewed and four themes identified; (a) mutual benefit, (b) emotional impact, (c) risk communication and (d) stoical attitudes to health. Participants reported minimal short-term impact on psychosocial health reported following receipt of a PRS. All participants communicated their genetic risk with their spouse/partner; however, some chose not to inform their children. Participants described themselves as having typical 'male' stoical responses to managing their health and that they did not feel the PRS results had an impact on their health behaviours.
conclusionsProviding an individualised PRS informing future risk of prostate cancer was well received. Overall, participants did not report being psychologically, socially or emotionally affected by receiving this genomic risk information. For those identified as being at higher risk it is important that there is access to healthcare professionals who are competent in discussing the meaning of the results.
trial registrationClinicalTrials.gov NCT03857477 , registered 26th Feb 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.